Shadi Swaidani

Shadi Swaidani

Auto-generated profile, based on publicly available information

Shadi Swaidani

Cleveland Clinic Lerner Research Institute, Center for Immunotherapy & Precision Immuno-Oncology, Cleveland, Ohio

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AWAvia D. Wilkerson
Avia D. Wilkerson
PPPrerana Bangalore. Parthasarathy
Prerana Bangalore. Parthasarathy
Nickolas StabelliniNickolas Stabellini
Nickolas Stabellini
CMCarley Mitchell
Carley Mitchell
PPPaul G. Pavicic
Paul G. Pavicic
Alberto J MonteroAlberto J Montero
Alberto J Montero
Purpose: A single arm, phase II trial of carboplatin, nab-paclitaxel, and pembrolizumab (CNP) in metastatic triple-negative breast cancer (mTNBC) was designed to evaluate overall response rate (ORR), progression-free survival (PFS), duration of response (DOR), safety/tolerability, overall survival (OS), and identify pathologic and transcriptomic correlates of response to therapy. Patients and Methods: Patients with ≤2 prior therapies for metastatic disease were treated with CNP regardless of tumor programmed cell death-ligand 1 status. Core tissue biopsies were obtained prior to treatment initiation. ORR was assessed using a binomial distribution. Survival was analyzed via the Kaplan–Meier method. Bulk RNA sequencing was employed for correlative studies. Results: Thirty patients were enrolled. The ORR was 48.0%: 2 (7%) complete responses (CR), 11 (41%) partial responses (PR), and 8 (30%) stable disease (SD). The median DOR for patients with CR or PR was 6.4 months [95% confidence interval (CI), 4–8.5 months]. For patients with CR, DOR was >24 months. Overall median PFS and OS were 5.8 (95% CI, 4.7–8.5 months) and 13.4 months (8.9–17.3 months), respectively. We identified unique transcriptomic landscapes associated with each RECIST category of radiographic treatment response. In CR and durable PR, IGHG1 expression was enriched. IGHG1high tumors were associated with improved OS (P = 0.045) and were concurrently enriched with B cells and follicular helper T cells, indicating IGHG1 as a promising marker for lymphocytic infiltration and robust response to chemo-immunotherapy. Conclusions: Pretreatment tissue sampling in mTNBC treated with CNP reveals transcriptomic signatures that may predict radiographic responses to chemo-immunotherapy.

5 November 2021 in Blood
Verified
Journal Article
Open access
SSShadi Swaidani
Shadi Swaidani
YSYoung Jun Shim
Young Jun Shim
PRPatricia Rayman
Patricia Rayman
PPPaul G. Pavicic
Paul G. Pavicic
CDC. Marcela Diaz-Montero
C. Marcela Diaz-Montero
KMKeith R McCrae
Keith R McCrae
Background: Venous thromboembolism (VTE) is an important immune-related adverse event (irAE) associated with immune checkpoint inhibitors (ICI) cancer therapy. To better understand the pathogenesis of ICI-induced VTE during ICI treatment, we utilized a murine model of cancer associated thrombosis (CAT) to examine the impact of ICI treatment on the development of flow restriction-induced thrombosis. Methods A syngeneic colon carcinoma murine model (CT26) on BALB/c background was utilized to evaluate venous thrombosis following inferior vena cava (IVC) ligation. Non-tumor-bearing and tumor-bearing animals were treated with therapeutic doses of ICI: anti-programmed cell death receptor 1 antibody (anti-PD1) and cytotoxic T‐lymphocyte-associated protein 4 (anti‐CTLA4) or isotype control antibodies. Mice underwent surgical treatment for IVC ligation followed by surgical retrieval of thrombus. Western blot analysis was performed on plasma cleaved high molecular weight kininogen (cHK), and citrullinated histone H3 (CitH3). Results Tumor-bearing mice undergoing IVC ligation after anti-PD1 and anti-CTLA4 infusion developed larger thrombi compared to mice treated with isotype control IgG. Thrombus weights in CT26 tumor-bearing mice treated with ICI (19.56±4.41 mg) were significantly increased compared to those in mice treated with isotype control IgG (14.67±2.76 mg) (P=0.043). The weight of thrombi in non-tumor-bearing mice was not affected by ICI treatment (9.25±2.22 mg with control IgG vs 9.33±1.15 mg with ICI). In addition, there was a significant increase in thrombus length in mice treated with ICI (9±1.02 mm vs 7.61±0.99 mm with IgG, P=0.039). Cleaved high molecular weight kininogen (cHK), an indicator of contact activation was increased in plasma pre-IVC occlusion from ICI-treated mice compared to IgG-treated mice (68% vs 38% in HK cleavage). Citrullinated histone H3 (CitH3), a NETosis marker, was elevated in plasma (and in thrombus) post-IVC occlusion from ICI-treated mice compared to that of IgG-treated mice. Conclusions ICI treatment of tumor-bearing mice undergoing flow restriction-induced thrombosis resulted in enhanced clot formation. Larger thrombi in ICI treated mice was accompanied with enhanced contact activation and NETosis marker CitH3.

5 January 2024
Verified
Other
Open access
AWAvia D. Wilkerson
Avia D. Wilkerson
PPPrerana Bangalore Parthasarathy
Prerana Bangalore Parthasarathy
Nickolas StabelliniNickolas Stabellini
Nickolas Stabellini
CMCarley Mitchell
Carley Mitchell
PPPaul G. Pavicic
Paul G. Pavicic
Alberto J MonteroAlberto J Montero
Alberto J Montero
Purpose:A single arm, phase II trial of carboplatin, nab-paclitaxel, and pembrolizumab (CNP) in metastatic triple-negative breast cancer (mTNBC) was designed to evaluate overall response rate (ORR), progression-free survival (PFS), duration of response (DOR), safety/tolerability, overall survival (OS), and identify pathologic and transcriptomic correlates of response to therapy.Patients and Methods:Patients with ≤2 prior therapies for metastatic disease were treated with CNP regardless of tumor programmed cell death-ligand 1 status. Core tissue biopsies were obtained prior to treatment initiation. ORR was assessed using a binomial distribution. Survival was analyzed via the Kaplan–Meier method. Bulk RNA sequencing was employed for correlative studies.Results:Thirty patients were enrolled. The ORR was 48.0%: 2 (7%) complete responses (CR), 11 (41%) partial responses (PR), and 8 (30%) stable disease (SD). The median DOR for patients with CR or PR was 6.4 months [95% confidence interval (CI), 4–8.5 months]. For patients with CR, DOR was >24 months. Overall median PFS and OS were 5.8 (95% CI, 4.7–8.5 months) and 13.4 months (8.9–17.3 months), respectively. We identified unique transcriptomic landscapes associated with each RECIST category of radiographic treatment response. In CR and durable PR, IGHG1 expression was enriched. IGHG1high tumors were associated with improved OS (P = 0.045) and were concurrently enriched with B cells and follicular helper T cells, indicating IGHG1 as a promising marker for lymphocytic infiltration and robust response to chemo-immunotherapy.Conclusions:Pretreatment tissue sampling in mTNBC treated with CNP reveals transcriptomic signatures that may predict radiographic responses to chemo-immunotherapy.

5 January 2024
Verified
Other
Open access
AWAvia D. Wilkerson
Avia D. Wilkerson
PPPrerana Bangalore Parthasarathy
Prerana Bangalore Parthasarathy
Nickolas StabelliniNickolas Stabellini
Nickolas Stabellini
CMCarley Mitchell
Carley Mitchell
PPPaul G. Pavicic
Paul G. Pavicic
Alberto J MonteroAlberto J Montero
Alberto J Montero
Heat map of Reactome Pathway Enrichment (Top 25, Bottom 25, and selected pathways) by pairwise comparison of radiographic response category (CR, PR, SD, PD)

5 January 2024
Verified
Other
Open access
AWAvia D. Wilkerson
Avia D. Wilkerson
PPPrerana Bangalore Parthasarathy
Prerana Bangalore Parthasarathy
Nickolas StabelliniNickolas Stabellini
Nickolas Stabellini
CMCarley Mitchell
Carley Mitchell
PPPaul G. Pavicic
Paul G. Pavicic
Alberto J MonteroAlberto J Montero
Alberto J Montero
Purpose:A single arm, phase II trial of carboplatin, nab-paclitaxel, and pembrolizumab (CNP) in metastatic triple-negative breast cancer (mTNBC) was designed to evaluate overall response rate (ORR), progression-free survival (PFS), duration of response (DOR), safety/tolerability, overall survival (OS), and identify pathologic and transcriptomic correlates of response to therapy.Patients and Methods:Patients with ≤2 prior therapies for metastatic disease were treated with CNP regardless of tumor programmed cell death-ligand 1 status. Core tissue biopsies were obtained prior to treatment initiation. ORR was assessed using a binomial distribution. Survival was analyzed via the Kaplan–Meier method. Bulk RNA sequencing was employed for correlative studies.Results:Thirty patients were enrolled. The ORR was 48.0%: 2 (7%) complete responses (CR), 11 (41%) partial responses (PR), and 8 (30%) stable disease (SD). The median DOR for patients with CR or PR was 6.4 months [95% confidence interval (CI), 4–8.5 months]. For patients with CR, DOR was >24 months. Overall median PFS and OS were 5.8 (95% CI, 4.7–8.5 months) and 13.4 months (8.9–17.3 months), respectively. We identified unique transcriptomic landscapes associated with each RECIST category of radiographic treatment response. In CR and durable PR, IGHG1 expression was enriched. IGHG1high tumors were associated with improved OS (P = 0.045) and were concurrently enriched with B cells and follicular helper T cells, indicating IGHG1 as a promising marker for lymphocytic infiltration and robust response to chemo-immunotherapy.Conclusions:Pretreatment tissue sampling in mTNBC treated with CNP reveals transcriptomic signatures that may predict radiographic responses to chemo-immunotherapy.

5 January 2024
Verified
Other
Open access
AWAvia D. Wilkerson
Avia D. Wilkerson
PPPrerana Bangalore Parthasarathy
Prerana Bangalore Parthasarathy
Nickolas StabelliniNickolas Stabellini
Nickolas Stabellini
CMCarley Mitchell
Carley Mitchell
PPPaul G. Pavicic
Paul G. Pavicic
Alberto J MonteroAlberto J Montero
Alberto J Montero
Differential IGHG1 expression between the IGHG1high (highest tertile) versus IGHG1low (lower tertiles) groups